Skip to content
OpenCapital
Get started

Innovate VATE Life Sciences — Income from operations

Other segment segments

Infrastructure
$19.7M+129%
Spectrum
$200K—

Other financials

Income statement

See full
Revenue$364.8M+33.0%
Gross profit$53.5M+17.6%
Operating income$10.0M+194%
Net income-$16.8M+31.4%
EPS (diluted)-$1.29+31.7%

Balance sheet

See full
Cash & equivalents$134.6M+297%
Total debt$1.4B+11.6%
Total equity-$256.3M-25.5%
Total assets$936.8M+7.9%

Cash flow

See full
Operating cash flow$45.5M+423%
CapEx$200.0K-95.7%
Free cash flow$45.3M+341%

Valuation

See full
Market cap$254.69M+274%

Where this comes from

Reported directly by Innovate in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: Innovate’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Innovate's life sciences — income from operations.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Innovate's life sciences — income from operations?
Innovate (VATE) reported life sciences — income from operations of -$2.2M in Q1 2026.
How has Innovate's life sciences — income from operations changed year-over-year?
Innovate's life sciences — income from operations increased by 26.7% year-over-year, from -$3M to -$2.2M.
What is the long-term trend for Innovate's life sciences — income from operations?
Over 2 years (2023 to 2025), Innovate's life sciences — income from operations has grown at a -14.8% compound annual growth rate (CAGR), from -$15M to -$10.9M.
What does life sciences — income from operations mean?
Represents the operating profit or loss generated by the Life Sciences business segment after deducting operating expenses from segment revenue. This metric measures the core profitability of the segment's activities, excluding interest, taxes, and non-operating items.